The classical dipeptidyl peptidase-4 (DPP-IV) inhibitors that protect the GLP-1 peptide from degradation have been used successfully as therapeutic reagents for T2D [52]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.